Primary non-Hodgkin's lymphoma of the infratemporal fossa: a rare case report
© Thakur et al; licensee BioMed Central Ltd. 2009
Received: 11 May 2009
Accepted: 21 June 2009
Published: 21 June 2009
The head and neck are two of the most common sites of extranodal non-Hodgkin's lymphoma (NHL). However, primary tumors of the infratemporal fossa are infrequent, and NHL in this region is extremely rare.
We present a case of a 41-year-old female that presented with swelling in the right preauricular region that had persisted for the past two years. The patient was diagnosed as having a small lymphocytic NHL. She initially underwent chemo-radiation but reported relapse. The tumor was excised and again the patient underwent chemotherapy. The patient remained symptomatic and developed a second primary squamous cell carcinoma in the right retromolar trigone.
Discussion and conclusion
We discussed NHL with an emphasis on extranodal manifestations. Extranodal NHL that is limited to a single site can be managed by surgery and regular follow up. To the best of our knowledge, this is only the second case of primary NHL of the infratemporal fossa to be reported in the literature.
The head and neck are some of the most common sites of extranodal non-Hodgkin's lymphoma , with Waldeyer's ring being the most common site of manifestation within the region. The oral cavity, salivary glands, thyroid gland, paranasal sinuses, nasal cavity, parapharyngeal space, larynx, and infratemporal fossa are the other sites in which NHL may occur in the region [1–9]. However, primary tumors of the infratemporal fossa are infrequent, and NHL in this region is extremely rare [5–10]. In this report, we present a new case of extranodal NHL arising in the infratemporal fossa, the second such case to be reported in the literature. We reviewed the literature on non-Hodgkin lymphoma with a special emphasis on extranodal manifestations.
In July 2006, a 41-year-old female presented with a swelling in the right preauricular region, which had persisted for the past two years, and was having difficulty opening her mouth for the past four months. The swelling was insidious in onset and progressive. In the first six months, the patient indicated the swelling was painless, only later becoming painful as the size increased.
The gastrointestinal tract, followed by the head and neck, is the most common site of extranodal NHL , with the head and neck contributing to about 11% to 33% of total cases [11, 12]. However, NHL is very rare in the superficial tissues of the head and neck region .
NHL is predominantly found in males of Caucasian descent [1, 2, 9, 13]. Other risk factors [1, 2, 9, 13–17] for the development of NHL include inherited and acquired immunodeficiency diseases, EBV, H. pylori and HTLV-I infections, chromosomal abnormalities, drug induced immunocompromised states, autoimmune diseases (e.g., rheumatoid arthritis and Sjogren's disease), exposure to pesticides and radiation, phenytoin therapy, previous history of Hodgkin's disease or chemotherapy, and excessive intake of meat and fat.
Extranodal NHL may present as a painless and progressively expanding lump or a widespread disease. The patient may be without any systemic symptoms ('A' symptoms) or may have night sweating, fever, and/or weight loss of greater than 10% of total body weight, which constitutes 'B' symptoms. FNAC gives a clear diagnosis of lymphoma and an uncrushed biopsy should be performed to ensure the accurate histological grading of the lymphoma .
In the head and neck, diffuse lymphoma (intermediate-grade) predominates, with diffuse large-cell lymphoma being the most common histological type of NHL [1, 2, 9]. B cells comprise the most common NHL of the head and neck, although T-cell lymphoma is common in the nasal cavity and nasopharynx [18, 19].
The accurate staging of extranodal NHL is important for effective planning of the treatment approach . Staging is determined by a detailed history, clinical examination, and radiological investigations. Conley et al.  found nodal disease in 50% of all cases at the time of presentation or during management, and they advised a detailed work up of all patients. It is further recommended that all cases of NHL should undergo a complete evaluation [1, 8, 9, 13–17], including a complete hemogram, liver and renal functions, serum 2-microglobulions, chest X-ray, bone marrow biopsy, gallium scan, and cerebrospinal fluid analysis, as well as CT scans of the abdomen, pelvis, and bones. As a majority of our patients are low-income, initially we undertake ultrasonography of the abdomen and X-rays of the pelvis, vertebra, and femurs. Then, if required, a CT is performed in suspicious cases.
The Ann Arbor staging system classifies lymphoma in four stages (I-IV) with 'A' and 'B' symptoms and the recently added 'E' sub stage [15, 17] for localized, solitary involvement of extra-lymphatic tissue, excluding the liver and bone marrow.
The treatment of NHL is a controversial issue [1, 9, 13–17, 20]. It consists of chemotherapy, radiotherapy, or surgery. Sometimes, in cases of limited extranodal NHL, only surgery without chemotherapy or radiotherapy is used . However, the main role of surgery is diagnostic only and rarely used for a cure , as in our case. In contrast, combined modalities, including surgery, chemotherapy, or radiotherapy, are used to treat advance NHL [13–17]. In stage I and II low grade extranodal lymphomas of the head and neck, radiotherapy is the first line of treatment, although the use of chemotherapy has also been advocated [1, 9, 13–17, 20]. Chemotherapy is the standard treatment for intermediate grade lymphomas [13–17, 20]. The addition of an anti-CD20 monoclonal antibody (rituximab) in the CHOP regimen (R-CHOP) has demonstrated promising results and is now frequently used for treatment of lymphomas. A total of 3–4 cycles of this regimen followed by radiotherapy are quite effective in the treatment of stage I and non-bulky stage II NHL; however, bulky stage II-IV tumors need 6–8 cycles of this chemotherapy. Bleomycin, etoposide, lomustine, carmustine, ifosfamide, and mitoxantrone are other chemotherapeutic agents used to treat NHL [17, 20]. Advance stage and high grade NHL warrants aggressive chemotherapy and treatment is generally palliative. Autologous bone marrow transplantation is the treatment of choice for recurrent NHL that is still sensitive to chemotherapy. The use of radiolabeled, monoclonal antibodies (e.g., ibritumomab tiuxetan and tositumomab) and interferon have also been advocated, but clinical use is still limited [13–17, 21].
Prognosis is calculated according to the International Prognostic Index (IPI) for patients at or above the age of 60 years. It is calculated based on age, LDH levels, performance status, and the number of extranodal sites involved. Factors such as molecular features of the tumor, levels of cytokines and soluble receptors, and surrogate markers have also been implicated in accurate prognosis, but these are clinically still under investigation . The prognosis declines with an increase in the patient's age, LDH levels, histological grade, or stage of the NHL. According to the IPI, the 5-year survival for all ages is about 73%–83% for low grade, 51%–69% for low-intermediate, 43%–46% for high-intermediate, and 26%–32% for high-grade NHL . Shima et al.  found decreased (28%) 5-years survival rates in young patients (≤ 20-years-old) irrespective of the stage of extranodal NHL.
A primary NHL of the infratemporal region is a rare clinical entity, and we found only one previous report of isolated NHL of the temporal region . This report documented a 65-years-old female with painless temporal swelling. A complete excision was performed and the patient had no recurrence, even in the absence of chemo- or radiotherapy.
This is the second case of primary NHL of the infratemporal fossa to be reported in the literature. The case discussed in this report was of clinical importance, as the patient had localized isolated primary NHL of the temporal region that was excised after failed chemoradiation. Histological examination found small lymphocytic-type NHL, which is infrequent in the head and neck region [1, 2]. The patient had a complete recovery but subsequently presented with radiation-induced second primary squamous cell carcinoma. Limited extranodal NHL can be managed by surgery alone, and radiotherapy has only a limited efficacy and potential side effects, including the induction of a second primary tumor.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Shima N, Kobashi Y, Tsutsui K, Ogawa K, Maetani S, Nakashima Y, Ichijima K, Yamabe H: Extra nodal Non-Hodgkin's Lymphoma of the Head and Neck: A Clinicopathological study in the Kyoto-Nara Area of Japan. Cancer. 1990, 66: 1190-7. 10.1002/1097-0142(19900915)66:6<1190::AID-CNCR2820660619>3.0.CO;2-U.View ArticlePubMedGoogle Scholar
- Conley S, Staszak C, Clamon G, Maves M: Non-Hodgkin's lymphoma of the head and neck. The University of Iowa experience. Laryngoscope. 1987, 97: 291-300. 10.1288/00005537-198703000-00007.View ArticlePubMedGoogle Scholar
- Kayhan FT, Ozkul N: Case report: extranodal non-Hodgkin's lymphoma of the parapharyngeal space. Auris Nasus Larynx. 1999, 26: 201-5. 10.1016/S0385-8146(98)00083-2.View ArticleGoogle Scholar
- Qureshi SS, Shet TM, Nagarajan G, Dcruz AK: Extranodal non-Hodgkin's lymphoma of the parapharyngeal space. Indian J Med Sci. 2006, 60 (4): 159-161.View ArticlePubMedGoogle Scholar
- Larson DL, Robblns KT, Butler JJ: Lymphoma of the Head and Neck: A Diagnostic Dilemma. Am J Surg. 1984, 148 (4): 433-437. 10.1016/0002-9610(84)90364-7.View ArticlePubMedGoogle Scholar
- Peerless AG, Lee KJ, Friedman SI: Non-Hodgkins lymphoma of the infratemporal fossa: a case report. Otolaryngology. 1978, 86 (5): ORL-704-ORL-709.Google Scholar
- Shaheen OH: Swelling of the infratemporal fossa. J Laryngol Otol . 1982, 96: 817-36. 10.1017/S0022215100093166.View ArticlePubMedGoogle Scholar
- Mitchell RB, Brown NW, Chappell ME: Non-Hodgkin's lymphoma presenting as an isolated temporal soft tissue swelling. J Laryngol Otol. 1996, 110: 161-2. 10.1017/S0022215100133043 .Google Scholar
- Hanna E, Wanamaker J, Adelstein D, Tubbs R, Lavertu P: Extranodal Lymphomas of the Head and Neck: A 20-Year Experience. Arch Otolaryngol Head Neck Surg. 1997, 123: 1318-23.View ArticlePubMedGoogle Scholar
- Tiwari R, Quak J, Egeler S, Smeele L, Waal IV, Valk PV, Leemans R: Tumors of the Infratemporal Fossa. Skull Base Surg. 2000, 10 (1): 1-9. 10.1055/s-2000-6789.PubMed CentralView ArticlePubMedGoogle Scholar
- Cobleigh M, Kennedy J: Non Hodgkin's lymphomas of the upper aerodigestive tract and salivary glands. Otolaryngol Clin North Am. 1986, 19 (4): 685-710.PubMedGoogle Scholar
- Wulfrank D, Speelman T, Pauwels C, Roels H, De Schryver A: Extranodal Hodgkin's lymphoma of the head and neck. Radiother Oncol. 1987, 8: 199-207. 10.1016/S0167-8140(87)80243-8.View ArticlePubMedGoogle Scholar
- Lymphoma. Available at the U.S. National Medical library & National Institute of health website. Accessed 28th Feb 2009, [http://www.nlm.nih.gov/medlineplus/lymphoma.html]
- Non-Hodgkin's lymphoma. Available at National Cancer Institute website. Accessed 28th Feb 2009, [http://www.cancer.gov/cancertopics/types/non-hodgkin]
- Malignancies of Lymphoid Cells. Harrison's Principles of Internal Medicine. 2008, The McGraw-Hills Companies Inc, [http://www.accessmedicine.com]17
- Treatment of extranodal Non-Hodgkin's lymphoma. Available at American Cancer Society website. [http://www.cancer.org/docroot/CRI/content/CRI_2_4_4X_Treatment_of_Extranodal_Non-Hodgkins_Lymphoma_32.asp]
- Foon KA, Geskin LJ, Ghobrial I, Jacobs SA: The Non-Hodgkin Lymphomas. Williams Hematology. Edited by: Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT. 2007, The McGraw-Hills Companies Inc, [http://www.accessmedicine.com]7Google Scholar
- Yamanka N, Harabuchi Y, Sambe S, Shido F, Matsuda F, Kataura A, Ishii Y, Kikuchi K: Non-Hodgkin's lymphoma of Waldeyer's ring and nasal cavity: Clinical and immunologic aspects. Cancer. 1985, 56 (4): 768-76. 10.1002/1097-0142(19850815)56:4<768::AID-CNCR2820560412>3.0.CO;2-W.View ArticleGoogle Scholar
- Chan JK, Ng CS, Lau WH, Lo ST: Most nasal/nasopharyngeal lymphomas are peripheral T-cell neoplasms. Am J Surg Pathol. 1987, 11: 418-29. 10.1097/00000478-198706000-00002.View ArticlePubMedGoogle Scholar
- Chu E, Sartorelli AC: Cancer Chemotherapy. Basic & Clinical Pharmacology. Edited by: Katzung BG. 2007, The McGraw Hill Companies Inc. Singapore, 878-907. 10Google Scholar
- Lake DF, Briggs AD, Akporiaye ET: Immunopharmacology. Basic & Clinical Pharmacology. Edited by: Katzung BG. 2007, The McGraw-Hill Companies Inc. Singapore, 908-33. 10Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.